4D Molecular Therapeutics to Present Updated Clinical Data with 4D-310 in Fabry Disease Patients in Platform Presentation at the 18th Annual WORLDSymposiumGlobeNewsWire • 02/02/22
4D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for the Treatment of X-linked Retinitis PigmentosaGlobeNewsWire • 01/10/22
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-150, a Dual-Transgene Intravitreal Gene Therapy for Patients with wet AMDGlobeNewsWire • 01/06/22
4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2021 ConferenceGlobeNewsWire • 11/23/21
4D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and Provides Operational HighlightsGlobeNewsWire • 11/10/21
4D Molecular Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewsWire • 10/29/21
4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1/2 Clinical Trial in Patients with ChoroideremiaGlobeNewsWire • 10/25/21
4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Clinical Trial in Patients with Advanced X-linked Retinitis Pigmentosa at the ASRS Annual MeetingGlobeNewsWire • 10/10/21
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150, a Dual-Transgene Intravitreal Gene Therapy for Patients with wet AMDGlobeNewsWire • 10/06/21
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-710, an A101 Vector-based, Aerosol-delivered Gene Therapy for the Treatment of Cystic Fibrosis Lung DiseaseGlobeNewsWire • 10/06/21
4D Molecular Therapeutics to Participate in Chardan's 5th Annual Genetic Medicines ConferenceGlobeNewsWire • 09/29/21
4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual MeetingGlobeNewsWire • 09/24/21
4D Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational HighlightsGlobeNewsWire • 08/12/21
4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination of Roche Collaboration and LicenseGlobeNewsWire • 06/24/21
4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational HighlightsGlobeNewsWire • 05/13/21
4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DMEGlobeNewsWire • 05/12/21
4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution PlatformGlobeNewsWire • 05/04/21
4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care ConferenceGlobeNewsWire • 04/30/21
4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate StudiesGlobeNewsWire • 04/27/21
4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational HighlightsGlobeNewsWire • 03/25/21
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry DiseaseGlobeNewsWire • 03/09/21
